natgillin/translations-raw huggingface dataset:
The process of claim 23, wherein the reaction effluent (28) further comprises organic acids, and wherein the catalytic hydrotreatment zone further hydrodeoxygenates and/or decarboxylates the hydrothermolysis effluent. 
Postupak u skladu s patentnim zahtjevom 13, naznačen time, da reakcijska otpadna tekućina (28) nadalje sadržava organske kiseline i pri čemu se u zoni katalitičke hidroobrade dodatno provodi hidrodeoksigenacija i / ili dekarboksilacija otpadne tekućine hidrotermolize.
Current sensor (25) according to claim 1, characterised in that the air-core coil is a Rogowski coil (29). 
Strujni senzor (25) u skladu s patentnim zahtjevom 1, naznačen time, da namotaj bez jezgre jest Rogowski namotaj (29).
The method of claim 7, wherein the method further comprises the steps of packing a column with the carriers onto which the psicose-epimerase and the D-glucose isomerase are immobilized and supplying the carrier-packed column with a D-fructose solution. 
Postupak prema jednom od zahtjeva 6 ili 7, naznačen time da postupak nadalje obuhvaća korake pakiranja kolone s nosačima na koje su imobilizirani GRAS sojevi koji eksprimiraju psikoza-epimerazu i D-glukoza izomerazu i opskrbljivanje pakirane kolone s nosačem s otopinom D-fuktoze.
reacting casein with at least one succinylation agent to form an aqueous suspension of succinylcasein, and 
reakcije kazeina s najmanje jednim sukcinilacijskim sredstvom, kako bi se dobilo vodenu suspenziju sukcinilkazeina, te
The compound or a pharmaceutically acceptable salt thereof or the pharmaceutical composition for use of claim 17, or the use according to claim 21, wherein the hyperproliferative disorder is breast cancer. 
Spoj za uporabu u skladu s patentnim zahtjevom 1, naznačen time, da je hiper-proliferativni poremećaj benigna hiperplazija prostate. Spoj za uporabu prema zahtjevu 1, naznačen time, da je hiper-proliferativni poremećaj rak dojke.
A sliding bearing (110; 210; 310) according to claim 2, wherein said organic fillers are carbon fibers in percentages ranging between 5 % and 30% by weight. 
Klizni ležaj (110; 210; 310) u skladu s patentnim zahtjevom 2, naznačen time, da su organska punila ugljična vlakna u postotcima u rasponu od 5% do 30% težinskog udjela.
the affinity is less than or equal to about 10-7M. 
(di) afinitet je manji od ili jednak oko 10'M.
adding the product of step (v) to a portion of the mixture obtained in step (i); and 
(vi) dodavanje produkta iz koraka (v) dijelu smjese dobivene u koraku (1); i
The surfactant can facilitate their own entry and that of other material into the body, which thus enters in to the systemic circulation (Lieberman, H.A., Rieger, M.M. and Banker, G.S., Eds., Pharmaceutical Dosage Forms: Disperse Systems, 2nd ed., Vol. 
Surfaktanti mogu olakšati vlastiti ulaz i ulaz ostalog materijala u tijelo, koji prema tome ulazi u sistemsku cirkulaciju (Lieberman, H.A., Rieger, M.M. i Banker, G.S., Ur., Pharmaceutical Dosage Forms: Disperse Systems, 2. izd., Vol.
The spreading-material container according to claim 12, wherein the liquid tank comprises, at least partly, of an elastic material, so that it can expand and contract. 
Spremnik tekućine u skladu s bilo kojim od patentnih zahtjeva 12 ili 13, naznačen time što se spremnik tekućine (10) u najmanju ruku djelomično sastoji od elastičnog materijala, tako da se može proširiti poput balona.
Already after 24 hours maintenance at 100% air humidity, Meldonium mass is increased by 10% because of water absorption, the substance being transformed into a syrup. 
Već nakon 24 sata držanja pri 100%-tnoj zračnoj vlazi, masa meldonija poraste za 10% zbog upijanja vode, pri čemu se ta tvar pretvori u sirup.
Use according to claim 1 in which W is O, S(O)n (where n is 0, 1 or 2), CR1R2 or NR15 where R15 is hydrogen or methyl. 
Uporaba prema zahtjevu 1, naznačena time da W je O, S(O), (pri čemu je n 0, 1 ili 2), CR'R? ili NR" pri čemu je R'* vodik ili metil.
A crystalline form according to claims 5 or 6 characterized by a differential scanning calorimetry curve to have an onset of melting which is comprised in the range 218-226 °C. 
Kristalna forma prema zahtjevima 5 i 6, naznačena time što krivulja diferencijalne skenirajuće kalorimetrije ima početak topljenja u opsegu 218-226%C.
The compound of claim 1, selected from 
Spoj prema patentnom zahtjevu 1, odabrano iz skupine koja se sastoji od:
nitro, halogen, substituted and unsubstituted alkyl, 
(3) nitro, (4) halogen, (5) supstituirani i nesupstituirani alkil,
The isolated fractions contained only very minor concentrations of contaminants. 
Izolirane frakcije su sadržavale samo vrlo male koncentracije onečišćenja.
is hydrogen, halo, cyano, Ar, Het, alkyl, and alkyloxy; p is an integer equal to 1 or 2; 
R' je vodik, halo, cijano, Ar, Het, alkil, te alkiloksi; p je cijeli broj jednak 1 ili 2;
m is 0 and B is a group of formula 
M je 0, a B je skupina iz formule [image] pri čemu
A composition according to any preceding claim wherein the terpene component comprises a terpene have the general structure C10H16. 
Sastav temeljem bilo kojeg od prethodnih zahtjeva gdje sastojak terpen sadrži terpen s općom strukturom C10H16.
on the IFN-Y Standard curve, provided with the kit, fitted by a Sigmoidal dose-response (4PL) Log/Log transformed, thus obtaining the x values (IFN-Y concentrations) (GraphPad Prism). 
na Standardnoj krivulji INF-y koja je dostupna u kompletu kemikalija, a koja je prilagođena Sigmoidalnom odgovoru na dozu (4PL) tako da je Log/Log transformirana što donosi vrijednosti x (INF-y koncentracije) (GraphPad Prism).
Particularly preferred are those constitutively active IKKa and IKKB mutants comprising the amino acid residues 25 to 769 of SEQ ID NO:2 or the amino acid residues 18 to 773 of SEQ ID NO:5, preferably having the sequence of SEQ ID NO:2 or SEQ ID NO:5, or wherein the coding RNA sequence contains SEQ ID NO:3 or 6. 
(1) -konstitutivno aktivni IKKa mutant sadrži aminokiselinske ostatke 25 do 769 u SEQ ID NO:2; ili (1) konstitutivno aktivni IKKB mutant sadrži aminokiselinske ostatke 18 do 773 u SEQ ID NO:5. DC-i u skladu s patentnim zahtjevom 1, naznačeni time što konstitutivno aktivni mutanti IKKa 1 IKKf imaju slijed SEQ ID NO:2 odnosno SEQ ID NO:5, ili imaju RNA slijed SEQ ID NO:3 ili 6.
The gun barrel in accordance with claim 1, wherein the chemical composition in % by weight of the deformed material comprises: Content C 
Cijev za projektile u skladu s patentnim zahtjevom 1, naznačena time što je načinjena od deformiranog materijala kemijskog sastava u težinskim % sadržaj C
The mixture was poured onto crushed ice (300 g) and water (100 ml) added. 
Smjesa sc ulije preko smrvljenog Icda (300 g) 1 doda se voda (100 ml).
X-ray diffraction pattern of the Form C of the crystal form of (6S)-5-methyltetrahydrofolate calcium salt is essentially shown in FIG. 1; or 
Obrazac rendgenske difrakcije kristalnog oblika C (6S)-5-metiltetrahidrofolatne kalcijeve soli je prikazan u sljedećoj tablici:
In particular embodiments, the compound or pharmaceutical composition of the present disclosure is administered intravenously in an amount ranging from about 10 ug/kg/min to about 50 ug/kg/min, about 20 ug/kg/min to about 40 ug/kg/min, about 25 ug/kg/min to about 35 ug/kg/min, or about 30 ug/kg/min to about 40 ug/kg/min. 
Spoj patentnog zahtjeva 1 ili patentnog zahtjeva 2 ili farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 3- 7 za primjenu kao što je definirano u bilo kojem od patentnih zahtjeva 9-11, gdje spoj ili farmaceutska kompozicija se trebaju administrirati intravenski u količini koja je u opsegu od 10 ug spoja sa formulama (1) ili (2)/kg/minuti do 50 ug spoja sa formulama (1) ili (2)/kg/minuti.
casting the buffer mixture onto the polymeric film rendering a coated polymeric film drying said coated polymeric film. 
lijevanja puferske smjese na polimerni film, čime se dobije obloženi polimerni film; i
The system of claim 18, the cell composition further comprising a cell extract selected from the group consisting of: dermal cells, keratinocytes, fibroblasts, melanocytes, Langerhans cells, fat cells, bone marrow cells, muscle cells, osteoblasts, chondrocytes, periosteal membrane cells, corneal cells, umbilical cord cells, Schwann cells, tendon cells, pancreas islet cells, adipocytes, adipose stem cells, corneal limbal stem cells, corneal keratinocytes, satellite stem cells, myoblast progenitor stem cells, stem cells, cartilage cells, ligament cells, connective tissue cells, and gingival cells. 
Miješanje navedene plazme bogate krvnim pločicama dobivene u koraku (c) i/ili (d) s najmanje jednim ekstraktom stanica, pri čemu se isti ekstrakt odabire između keratinocita, stanica koštane srži, fibroblasta, stanica pokosnice ili rožnice, melanocita, Langerhansovih stanica, masnih stanica, mišićnih stanica poput mioblasta i satelitskih stanica, osteoblasta, hondrocita, stanica pupčane vrpce, mezenhimalnih matičnih stanica (MSCs), preadipocita, endotelnih stanica, Schwannovih stanica ili stanica Ahilove tetive.
A method for treating a patient suffering from a thermoregulatory dysfunction associated with menopause comprising administering paroxetine to said patient, wherein said paroxetine is in the form of a pharmaceutically acceptable mesylate salt, in amorphous or crystalline form, and mixtures thereof, wherein said paroxetine mesylate is administered in an amount, based on the paroxetine moiety, of 7.5 mg/day. 
HR P20181893 T1 PATENTNI ZAHTJEVI 1. Farmaceutski pripravak koji sadrži paroksetin ili njegovu farmaceutski prihvatljivu sol za uporabu u liječenju valunga koji su povezani s hormonalnim poremećajima uslijed menopauze, naznačen time da se pripravak paroksetina treba primjenjivati u količini od 7.5 mg/dan ovisno o udjelu paroksetina, s iznimkom nazalne primjene.
The system according to claim 1 or 2, characterised in that said first stage (2) comprises means (22, 23) for separating by gravity said heavy fraction from said mixture and for discharging (24) said separate heavy fraction. 
Sustav prema zahljevu 1 ili 2, naznačen time što prva faza (2) obuhvaća sredstva (22, 23) za gravitacijsko razdvajanje teške frakcije od smjese 1 za izbacivanje (24) tako razdvojene teške frakcije.
Pharmaceutical composition according to item 15 containing dimethylfumarate at a dose range of 60 mg to 250 mg and teriflunomide at a dose range of 0.5 mg to 3 mg or fingolimod at a dose range of 0.025 mg to 0.20 mg or laquinimod at a dose range of 0.025 mg to 0.125 mg. 
Kombinacija za uporabu prema zahtjevu 16. naznačena time što sadrži dimetilfumarat u rasponu doze od 60 mg do 250 mg i teriflunomid u rasponu doze od 0,5 mg do 3 mg ili fingolimod u rasponu doze od 0,025 mg do 0,20 mg.
A waterside facility according to any of the preceding claims, wherein the enclosure encloses one or more of: an accommodation unit for providing accommodation to a number of users; a catering facility for providing catering to a number of users. 
400; 500; 600) ograđuje jedno ili više od sljedećeg: jedinice za smještaj koja omogućuje smještaj korisnicima; objekta za ugostiteljstvo za pružanje ugostiteljske usluge korisnicima.
heating the intimate mixture while recording the DSC dissolution endotherm of the mixture, 
zagrijavanje bliske smjese uz bilježenje endoterme otapanja diferencijalnom skenirajućom kalorimetrijom (DSC) smjese,
The peptide may be prepared as a diacid (though this may involve intermediate protection of the glutamyl a-carboxyl as well as the amine) or as a mono- or diester, depending on the state of the starting amino acids. 
HR P20090134 T3 Sulfidni spojevi mogu se pripraviti kao dikiseline (premda ovo može uključiti zaštitu intermedijera glutamila a-karboksila kao amina) ili kao mono- ili diestera, ovisno o stanju početne amino kiseline.
Group Number of Animals 
Broj međunarodne objave:
is hydrogen, alkyl, alkoxyalkyl, alkylcarbonyl, alkylthiocarbonyl or unsubstituted or substituted benzyl, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, alkyl, haloalkyl, alkylthio, haloalkylthio, arylthio, alkoxy, haloalkoxy, alkylcarbonyl, haloalkylcarbonyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylamine, di(alkyl)amino; 
Rgje vodik, alkil, alkoksialkil, alkilkarbonil, alkiltiokarbonil ili nesupstituirani ili supstituirani benzil, gdje supstituenti mogu biti svaki neovisan jedan od drugoga i odabrani su iz skupine koja se sastoji od sljedećih: cijano, nitro, halogen, alkil, haloalkil, alkiltio, haloalkiltio, ariltio, alkoksi, haloalkoksi, alkilkarbonil, haloalkilkarbonil, alkilsulfinil, haloalkilsulfinil, alkilsulfonil, haloalkilsulfonil, alkilamino, di(alkil)amino;
coating the silicone fouling release top coat (v) with a removable polymeric film. A method of preparation of a coated structure comprising the step of coating at least part of the outer surface of the structure with a multilayer self-adhesive fouling release coating composition according to any of claim 1 to 8. 
Postupak priprave premazane strukture, naznačen time što se sastoji u koraku premazivanja u najmanju ruku dijela vanjske površine strukture višeslojnim samoljepljivim pripravkom za premazivanje, namijenjenim otpuštanju obraštaja u skladu s bilo koji u skladu s patentnim zahtjevom 6 do 9.
A hemihydrate form of the sodium salt of pemirolast. 
Hemihidratni oblik natrijeve soli pemirolasta.
X represents a heteroatom; 
predstavlja lanac;
is Hal, LA, O(LA), Cyc1 or Cyc2, and pharmaceutically acceptable salts, solvates, solvates of salts, or prodrugs thereof. 
R' je Hal, LA, O(LA), Cyc! ili Cyc", ili njegova farmaceutski prihvatljiva sol, solvat ili solvat soli.
Figure 2 shows a side view, with parts in section and parts removed for clarity, of a portion of the Figure 1 mixing member; 
Slika 2 prikazuje pogled sa strane dijela Slike 1 članka za miješanje, s dijelovima u presjeku, i radi jasnoće, bez odstranjenih dijelova;
A DNA molecule comprising a region encoding the variable heavy chain of an antibody according to claim 1 to 10 a region encoding the variable light chain of an antibody according to claims 1 to 10. 
DNK-molekula, naznačena time, da obuhvaća područje koje kodira varijabilni jaki lanac od protutijela prema zahtjevima od 1 do 10, te područje koje kodira varijabilni slabi lanac od protutijela prema zahtjevima od 1 do 10.
to form a composition; shaping the composition to form an extended release matrix formulation; and curing said extended release matrix formulation comprising at least a curing step of subjecting the extended release matrix formulation to a temperature which is at least the softening temperature of said polyethylene oxide for a time period of at least 5 minutes. 
Oblik za doziranje s produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 22, naznačen time da je u obliku tablete koja je napravljena izravnom kompresijom sastojaka i sušena najmanje podvrgavanjem navedene tablete na temperaturu od barem oko 60 °C ili pri barem oko 62 °C u vremenskom razdoblju od barem oko 1 minute, poželjno barem oko 5 minuta ili barem oko 15 minuta.
Oral pharmaceutical tablet for controlled release of mesalazine and process for obtaining it 
ORALNA FARMACEUTSKA TABLETA ZA KONTROLIRANO OTPUŠTANJE MESALAZINA I POSTUPAK NJEZINE PROIZVODNJE
The method according to claim 18, wherein the potassium salt is potassium chloride or potassium acetate. 
Metoda prema zahtjevu 17, gdje je kalijeva sol kalijev klorid ili kalijev acetat.
The grooming tool of claim 5 wherein the head includes a locking tab arrangement constructed and arranged to releasably lock the blade carrier in at least the first position and the second position. The grooming tool of claim 6 wherein: 
Alat za njegu (10) u skladu s patentnim zahtjevom 3, naznačen time što glava (14) ima sklop zabravljujućih jezičaca (86) takve konstrukcije i smještaja da odvojivo zabravljuju nosač oštrica (30) u najmanju ruku prvom položaju i drugom položaju.
a hardened composition formed from 
stvrdnutog pripravka dobivenog od
a first securing device for securing the first and second flanges to one another, 
prvo sredstvo (A) za čvrsto spajanje, koje je namijenjeno za međusobno pričvršćenje prve i druge prirubnice;
The process of paragraph 58, wherein said acid is glyoxylic acid. 
Postupak u skladu s patentnim zahtjevom 48, naznačen time što navedena kiselina je glioksilna kiselina.
A method of preparing the crystal form I according to claim 2, comprising the following steps of: 
Postupak pripreme kristalnog oblika I sukladno patentnom zahtjevu 2 ili 3, koji sadrži slijedeće korake:
placing in oral cavity of the patient with halitosis a single portion of chewing gum comprising at least one first region with gum base and at least a second fully water-soluble region without gum base, said chewing gum characterized by the presence of a synergistic combination of: 
Žvakaća guma koja se sastoji od barem prve regije s bazom za gume te barem druge u vodi potpuno topljive regije bez baze za gume, a rečena guma, naznačeno time da ima prisutnost sinergične kombinacije sljedećih:
is a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted C2-6 alkenyl group, an optionally substituted C3-8 cycloalkyl group, an optionally substituted C4-8 cycloalkenyl group, an optionally substituted C3-8 cycloalkyl-C1-6 alkyl group or an optionally substituted aryl group; and 
je atom vodika, atom halogena, po izboru supstituirana C1-6 alkilna skupina, po izboru supstituirana C2-6 alkenilna skupina, po izboru supstituirana C3-8 cikloalkilna skupina, po izboru supstituirana C4-8 cikloalkenilna skupina, po izboru supstituirana C3-8 cikloalkil-C1-6 alkilna skupina ili po izboru supstituirana arilna skupina; i
Significance criteria: ≥ 50% of maximum stimulation or inhibition Adrenergic a 2B Receptor: 
Signifikantni kriterij: > 50% maksimalne stimulacije ili inhibicije (b) Adrenergički ap receptor:
The method of claim 36, wherein the maximum expansion pressure of said synthetic substance, in fully confined conditions, is higher than 500 kPa. 
Postupak prema jednom ili više prethodnih zahtjeva, naznačen time, da je maksimalni tlak ekspanzije od spomenute sintetičke tvari (4), u potpuno ograničenim uvjetima, veći od 500 kPa.
data obtained from the gene expression profiles for the training samples and the gene expression profile for the test sample are processed via normalization methods prior to analysis. 
(iv) podatke dobivene iz profila ekspresije gena kod uzoraka za obučavanje, a profil ekspresije gena za ispitivani uzorak se obrađuje postupcima normaliziranja prije analize.
melphalan flufenamide hydrochloride (J1), is dissolved in an organic solvent; water is added to the solution obtained in step a) in order to obtain a solution of said melphalan flufenamide hydrochloride (J1), or a pharmaceutically acceptable salt thereof, in a concentration of about 0.2-3.0 mg/ml; 
Postupak za pripravu liofiliziranog farmaceutskog pripravka u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da: a. = melfenalan-flufenamid hidroklorid (ITI) se otopi u organskom otapalu kako bi se dobila otopina melfalan flufenamid hidroklorida (J1); b.
All of the methods described herein above in this section "Aroma compounds" may furthermore contain a step e) removing at least part of one cation from the AX-REED liquid, while retaining at least 65% of said at least one micro-nutrient and at least 65% of said at least one aroma compound in said liquid, thereby obtaining a CX-REED liquid, wherein said cation is removed through an Cation Exchange Reverse Electro-Enhanced Dialysis (CX-REED) membrane stack. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time što postupak nadalje obuhvaća korak e), pri čemu korak e) obuhvaća uklanjanje najmanje dijela jednog kationa 1z tekućine AX-REED uz zadržavanje najmanje 65 % navedene najmanje jedne mikro hranjive tvari u navedenoj tekućini, te se tako dobiva tekućina CX-REED, pri čemu se navedeni kation uklanja putem stoga membrana za kationsku izmjenu reverznom elektro poboljšanom dijalizom,,Cation Exchange Reverse Electro-Enhanced Dialysis" (CX-REED), te navedeni stog membrana sadrži i)
The residue was purified by flash chromatography (SiO2) using 10% ethyl acetate-hexanes. 
Ostatak se pročisti svjetlosnom kromatografijom (Si02) uporabom 10% etil acetat-heksana.
and f is the fraction of the total sample conditioned medium present in the portion of the cell culture conditioned medium not containing cells of the cell population; or when the ratio of the first percentage to the second percentage deviates from 1:1, calculating the fraction of viable cells by comparing the level of cell death-stable enzyme activity detected in steps (b) and (d) according to the formula: 
HR P20140825 T1 pri čemu i fje udio ukupnog uzorka kondicioniranog medija koji je prisutan u dijelu kondicioniranog medija stanične kulture koji ne sadržava stanice iz populacije stanica; i pri čemu kada je omjer postotka stanica prema postotku kondicioniranog medija stanične kulture u dijelu uzorka odstupa od 1:1, udio vijabilnih stanica u produktu preinačenog-tkiva se može izračunati prema formuli:
A delayed release drug formulation for oral administration to deliver a drug to the colon of a subject, said formulation comprising a core and a coating for the core, the core comprising a drug and the coating comprising an outer layer and an inner layer, wherein the outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria and a second polymeric material which has a pH threshold at pH 6.5 or above, and wherein the inner layer comprises a third polymeric material which is soluble in intestinal fluid, said third polymeric being a polycarboxylic acid polymer that is at least partially neutralised, wherein at least 10% of the carboxylic acid groups of the polycarboxylic acid polymer are in the form of carboxylate anions. 
Formulacija lijeka s produženim otpuštanjem za oralnu primjenu radi davanja lijeka u debelo crijevo pacijenta, pri čemu spomenuti pripravak sadrži: jezgro i prevlaku za jezgru, to jezgru koja sadrži lijek i ovojnicu koja sadrži vanjski sloj i unutarnji sloj; pri čemu vanjski sloj sadrži smjesu prvog polimernog materijala koji je osjetljiv na napad bakterija debelog crijeva i drugi polimerni materijal koji ima prag pH na pH 6 ili više, i pri čemu unutarnji sloj sadrži treći polimerni materijal koji je neionski polimer koji je topljiv u crijevnoj tekućini, ili gastrointestinalnoj tekućini, i najmanje jedan aditiv odabran iz puferskog sredstva i baze.
In addition, phosphorylase-dependent glycogen breakdown is also blocked by insulin (Bollen, M., and Stalmans,) (1992) Crit. 
Nadalje, razgradnja glikogena ovisnog o fosforilazi također blokira inzulin (Bollen, M., i Stalmans,) (1992) Crit.
In a concentrated foliar fertilizer product, the surfactant is preferably present in the aqueous suspension preparation at a concentration of 0.1% to 5%, especially preferably at a concentration of 0.25% to 1%. 
Pripravak u obliku vodene suspenzije u skladu s patentnim zahtjevom 1, naznačen time što je tenzid prisutan u koncentraciji od 0,25 % do 1 % u pripravku u obliku vodene suspenzije.
See also European Patent Publication No. 
Datum objave europskog patenta:
Also contemplated are chemical modifications that comprise the inclusion of a Cap1 structure to the 5′ untranslated region of the mRNA. In still other embodiments, the chemical modification comprises the inclusion of a sequence encoding human growth hormone (hGH) to the 3′ untranslated region of the mRNA. 
(vi) kemijska modifikacija podrazumijeva uključivanje Cap1 strukture u 5' netranslatirajuću regiju iRNK; ili (vii) kemijska modifikacija podrazumijeva uključivanje sekvence koja kodira ljudski hormon rasta (nGH) u 3' netranslatirajuću regiju iRNK.
2% corn starch and wherein the viscosity is in the range 25,000 to 130,000 cP. 
2% w/w kukuruznog škroba i naznačen time da je viskoznost u rasponu od 25,000 do 130,000 cP.
The injectable depot composition according to claim 1, wherein the mass ratio between the weight of the polymeric solution and the weight of the drug is about 6.66:1. 
Sastav u skladu s patentnim zahtjevom 8, naznačen time što je omjer mase između težine otopine sastoji se od polimera i otapala i lijeka je otprilike.